The discussion around the - 14% on the 50 person groupIt is important Josh and we thank you sincerely for posting "all thru the night"
People need to remember that our trial is unique and "cutting edge" ( our therapy called state-of-the-art by many ) The fact we offer a diagnostic ( The EAA, FDA apporoved in 2003 ) is important as it allows for the correct timing of the PMX ( Toraymyxin ) column's use. Clearly at a .9 level or higher, the endotoxin load is too great. The ability to measure the endotoxin level of the patient is a huge advantage and EDT has proven this duirng the trial.
If you listen to Dr. Ronco, Dr. Kellum ( on our DSMB ), Dr. Bagshaw ( delveloping a PMX database ) or Dr. JL Vincent ( a global giant in critical care ) you'll realize that our approach and our results will be very important to the "Sepsis Story"
I am curious to hear from the global KOL's at Vicenza as they interpret our results and the important of the "theranostic approach" ( therapy + diagnostic ) moving forward.
I am sitting tight and paying attention to the message being sent to the less informed public.
The NEGATIVE finding on the HIGHLY endotoxemic is a positive for determining when and where we use PMX.
GLTA,
Jorge